Pharmacodynamic measurements of lipid parameters: percent change from baseline at day 113 and percent change from baseline compared to placebo for ANGPTL3, TG, VLDL-C, non-HDL-C, LDL-C, HDL-C, Apo CIII, total cholesterol, Apo B, Apo AI and Lp(a) in participants with hepatic steatosis receiving repeat doses of 200 mg of ARO-ANG3